Bergovec M
Zavod za kardiovaskularne bolesti Interne klinike Medicinskog i stomatoloskog fakulteta, Klinicka bolnica Sestre milosrdnice Zagreb.
Lijec Vjesn. 1993 May-Jun;115(5-6):170-8.
The management of acute myocardial infarction has dramatically changed in the last decade. The conservative approach with bed rest, oxygen therapy, pain relief and prevention of complications--the former cornerstones of the treatment of acute myocardial infarction--are now being replaced with new, more aggressive forms of therapy, including early administration of thrombolytic agents. With the more than 100,000 patients studied in various clinical trials in the different parts of the world, the use of thrombolytic therapy is probably the most thoroughly studied medical intervention in human medical history. The results of these trials undoubtedly showed that thrombolytic therapy had a major impact on reducing mortality and preserving left ventricular function in patients with acute myocardial infarction. The purpose of this article is to review current new information on thrombogenesis and thrombolysis, the indications and contraindications of thrombolytic therapy, comparisons between different thrombolytic agents and the role of adjuvant antithrombotic therapy.
在过去十年中,急性心肌梗死的治疗方法发生了巨大变化。以往治疗急性心肌梗死的基石——卧床休息、氧疗、止痛及预防并发症等保守方法,如今正被新的、更积极的治疗方式所取代,包括早期使用溶栓药物。通过在世界各地不同临床试验中对超过10万名患者的研究,溶栓治疗的应用可能是人类医学史上研究最为深入的医学干预措施。这些试验结果无疑表明,溶栓治疗对降低急性心肌梗死患者的死亡率及保护左心室功能有重大影响。本文旨在综述目前有关血栓形成与溶栓的新信息、溶栓治疗的适应证与禁忌证、不同溶栓药物之间的比较以及辅助抗栓治疗的作用。